Acurable has announced the availability of its first product, AcuPebble SA100, a small wearable device which enables a fully automated and remote diagnosis of obstructive sleep apnoea (OSA).
Traditionally, the diagnosis of OSA has required multiple hospital visits for patients, and doctors have had to manually review and analyse data from a patient’s sleep study. AcuPebble SA100 automates this process.
AcuPebble SA100 gained CE mark approval in September 2020 and is the product of more than ten years of research led by Professor Esther Rodriguez-Villegas at Imperial College London.
OSA causes sufferers to repeatedly stop breathing while they are asleep, and can lead to serious health implications including high blood pressure, type 2 diabetes and dementia.
Prof. Rodriguez-Villegas, inventor of the technology and founder of Acurable, said: “Currently, only around 20% of people affected with sleep apnoea are diagnosed, and there are long waiting lists due to the scarcity of sleep clinics and the high costs of offering current sleep diagnostic tests. Furthermore, during the current Coronavirus pandemic, this challenge has been further exacerbated. There is a backlog of patients who weren’t seen during the height of the crisis and a reluctance from patients to travel to hospital. What’s more, doctors are looking for ways to treat patients remotely to reduce the risk of infection. Acurable’s effective at-home testing enables earlier, more accurate and more cost-effective diagnosis of sleep apnoea, which will improve patient care, reduce co-morbidities and the risk of contagion, and which could save millions in hospital resources.”
With AcuPebble SA100, patients undertake their sleep test remotely. The device continuously monitors the patient’s breathing and cardiac biosignals in a non-invasive way while they sleep, and then automatically interprets the results. The next day, doctors can see the diagnosis without having to manually review the data themselves, while patients do not need to attend outpatient appointments or stay overnight at a sleep clinic. AcuPebble is proven to have the diagnostic equivalence of multi-channel polygraphy - the current gold standard for ambulatory sleep apnoea diagnosis - with 94% PPV and 98% NPV in a recent trial at NHS Royal Free Hospital London.
Dr Swapna Mandal, a respiratory consultant at the Royal Free London NHS Foundation Trust, said: “It's thought that 1.5 million individuals in the UK have Obstructive Sleep Apnoea, and at the moment, 80% of those remain undiagnosed. That equates to one in 25 men and one in 50 women. A few years ago, we were maybe getting 500 or 600 referrals a year, we're now getting about 2,000. This was already a lot to deal with, especially given the long and often complex diagnostic pathway for sleep apnoea, but with the ongoing Coronavirus pandemic, we now have an even bigger backlog of patients to see. What’s more, we’re moving to a digital first approach, so we’re trying to reduce the number of appointments taking place in the hospital.
“Last year, we ran a clinical trial with Acurable which demonstrated that the AcuPebble SA100 has diagnostic equivalence to the current ambulatory gold standard for obstructive sleep apnoea diagnosis. This is great news, especially now, as it means we can diagnose more patients, reduce the number of times these patients need to visit a hospital, and ultimately improve quality of life for those patients.”
AcuPebble operates on the principle of acoustic sensing, whereby the body respiratory and cardiac functions generate sounds that can be recorded with a non-invasive wearable sensor. The acoustic signals are then transferred wirelessly to a mobile device and to the cloud, where patented algorithms automatically extract the physiological parameters used by doctors for the diagnosis and management of important conditions such as sleep apnoea, COPD, epilepsy and asthma.
In 2014, AcuPebble won the prestigious XPRIZE and Acurable has since been operating in stealth mode, focusing on perfecting the technology, building the team and obtaining all the regulatory approvals required to launch as a medical device. During this time, Acurable secured £2.1 million in seed funding from Kindred Capital and Alma Mundi Ventures, as well as two Innovate UK grants worth £1.4 million. Acurable has also conducted a large clinical trial at the NHS Royal Free Hospital in London which demonstrated the safety and effectiveness of AcuPebble SA100 against multi-channel polygraphy. Most recently, Rodriguez-Villegas was awarded the Silver Award by the Royal Academy of Engineering for her work creating the AcuPebble technology.
In addition to improving diagnosis of sleep apnoea, Acurable is also working on product solutions to help improve the diagnosis and management of several other serious conditions such as COPD, pneumonia, epilepsy and asthma.
